This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Earl G. Gross, MD
Veterans Administration Hospital University of Connecticut Medical Center Newington, CT 06111

Gary L. Peck, MD
Department of Dermatology University of Maryland School of Medicine 6th Floor 405 W Redwood St Baltimore, MD 21201

John J. DiGiovanna
Bldg 10, Room 12N238 Dermatology Branch National Cancer Institute National Institutes of Health Bethesda, MD 20892

Arch Dermatol. 1991;127(12):1849-1850.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The widespread and successful use of isotretinoin and etretinate for the treatment of cystic acne and severe forms of psoriasis has established oral synthetic retinoid therapy as an integral component of the dermatologic formulary. However, based on the acute mucocutaneous and systemic toxic reactions as well as the chronic skeletal toxic reactions observed with these agents, the need for a safer systemic retinoid is evident.

In preclinical animal testing, the observed toxic effects of therapy with fenretinide, n-(4-hydroxyphenyl) retinamide, (Fig 1) were considerably less than those observed with isotretinoin. ¹ In phase 1 clinical studies, in healthy human volunteers using doses up to 600 mg/d for 1 month, the observed clinical toxic effects were limited to mild elevations of aspartate aminotransferase, alkaline phosphatase, and triglyceride values (F. Minn, MD, PhD, McNeil Laboratories, Spring House, Pa, oral communication, 1984). It was concluded that 600 mg/d was minimally . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?